cCAM Biotherapeutics

Company Overview

Snapshot

Founded in January 2010, cCAM Biotherapeutics operated with 1–10 employees. The company raised $8M across one funding round from three investors, including Arkin Tech. A significant milestone occurred in July 2015 when cCAM Biotherapeutics was acquired by Merck.

Business overview

cCAM Biotherapeutics was a preclinical-stage company focused on the discovery and development of novel immunotherapies for cancer treatment. Its core product, CM-24, was a phase 1 monoclonal antibody designed to inhibit the immunosuppressive effect of CEACAM1, thereby enhancing the anti-tumor immune response of T and NK cells. The company operated within the Pharmaceuticals sector, specifically targeting the Drugs Discovery & Development segment within Health Tech & Life Sciences, and served the Life Sciences and Pharmaceuticals markets.

Strategic signal

In July 2015, cCAM Biotherapeutics was acquired by Merck for up to $605 million. This acquisition highlights the strategic value of cCAM Biotherapeutics' immunotherapy pipeline, particularly its lead candidate CM-24, and signals a strong validation of its research and development efforts in the competitive oncology market. For investors, this demonstrates the potential for significant returns through strategic exits in the biopharmaceutical sector, especially for companies developing innovative cancer treatments.

Company Intelligence Q&A

What was a key strategic development for cCAM Biotherapeutics?

In July 2015, cCAM Biotherapeutics was acquired by Merck for up to $605 million, leading to its full integration into Merck & Co. Inc.

When did cCAM Biotherapeutics initiate its Phase 1 trial for CM-24?

cCAM Biotherapeutics announced the initiation of its Phase 1 trial for CM-24, a novel immune checkpoint inhibitor for cancer immunotherapy, in April 2015.

Which investors participated in cCAM Biotherapeutics' funding round?

In September 2012, cCAM Biotherapeutics received funding from investors including Arkin Tech and OrbiMed.

What is the primary focus of cCAM Biotherapeutics' technology?

cCAM Biotherapeutics focused on the discovery and development of novel immunotherapies to treat cancer, with its lead product CM-24 being a monoclonal antibody that inhibits the immunosuppressive effect of CEACAM1.

What is the current status of cCAM Biotherapeutics?

cCAM Biotherapeutics is currently inactive, having been acquired by Merck in July 2015.